WealthPlan Investment Management LLC Cuts Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

WealthPlan Investment Management LLC reduced its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 53.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,330 shares of the company’s stock after selling 30,232 shares during the period. WealthPlan Investment Management LLC’s holdings in Hims & Hers Health were worth $637,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Main Management ETF Advisors LLC purchased a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $672,000. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $604,000. Royce & Associates LP increased its position in shares of Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after purchasing an additional 49,500 shares during the last quarter. Versor Investments LP purchased a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $634,000. Finally, International Assets Investment Management LLC purchased a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $6,790,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $60.41 on Friday. The company has a market cap of $13.20 billion, a P/E ratio of 137.31 and a beta of 1.35. Hims & Hers Health, Inc. has a one year low of $9.22 and a one year high of $64.84. The firm has a fifty day moving average of $32.06 and a two-hundred day moving average of $24.28.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the company from $32.00 to $18.00 in a report on Thursday, November 14th. TD Cowen restated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $25.13.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 33,513 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.38, for a total transaction of $1,118,663.94. Following the completion of the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $1,118,296.76. This represents a 50.01 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Melissa Baird sold 67,687 shares of the stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $44.71, for a total transaction of $3,026,285.77. Following the completion of the transaction, the chief operating officer now owns 706,872 shares of the company’s stock, valued at $31,604,247.12. This represents a 8.74 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,111,554 shares of company stock worth $33,865,763. 17.71% of the stock is owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.